tbuckley/cabot-search huggingface dataset:
Results of Removing a Normal Appendix
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adolescent Health
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infection with HTLV-III/LAV and transfusion-associated acquired immunodeficiency syndrome. Serologic evidence of an association
Authors: H. W. Jaffe
Journal: JAMA (1985)

We studied patients with transfusion-associated acquired immunodeficiency syndrome (AIDS) and their blood donors for serologic evidence of infection with human T-cell lymphotropic virus type III/lymphadenopathyassociated virus with two enzyme-linked immunosorbent assays and a Western blot assay. All 19 patients with AIDS were seropositive by at least one test. In all 28 donor sets containing "high-risk" donors, at least one donor was seropositive by one or more tests. Of 255 donors not considered high risk, two (0.8%) were seropositive by all three tests. When 30 seropositive high-risk donors were evaluated a median of 29 months after donation, four (13%) had developed AIDS and eight (27%) had lymphadenopathy. Our findings support the hypothesis that human T-cell lymphotropic virus type III/lymphadenopathy-associated virus causes AIDS and indicate that seropositive high-risk donors may be at relatively high risk for developing AIDS or related conditions themselves. (<i>JAMA</i>1985;254:770-773)
Sex Chromosome Mosaicism (XO/XX/XXY/XY) in a Phenotypic Female
Authors: Robert L. Kaufman
Journal: JAMA (1971)

A tall, 26-year-old phenotypic woman who had secondary amenorrhea and infertility was found to have four stem-line sex chromosome mosaicism with XO/XX/XXY/XY cell lines in lymphocytes and skin. Laparotomy disclosed a uterus, a structure in the right adnexal region resembling ovarian stroma, and hilar-cell hyperplasia in a left adnexal cyst. The usefulness of the pneumogynogram in the examination of patients with suspected gonadal dysgenesis, the cytogenetic approach to sex chromosome mosaics and the particular significance of a Y-containing cell line are emphasized.
ECG Challenge: July 8, 2014
Authors: Philip Podrid
Journal: Circulation (2014)

A 76-year-old man presents to the emergency department 4 hours after the onset of substernal chest burning that radiated to his throat and jaw.He initially thought that this was a gastrointestinal problem, but it persisted despite therapy with antacids.He therefore presented to the emergency department.What is the diagnosis?To submit your diagnosis, go to http://circ.ahajournals.org/letters
Interferon-gamma differentially regulates CD80 (B7-1) and CD86 (B7-2/B70) expression on human Langerhans cells
Authors: H. YOKOZEKI, I. KATAYAMA, O. OHKI, M. ARIMURA, K. TAKAYAMA, T. MATSUNAGA, T. SATOH, T. UMEDA, M. AZUMA, K. OKUMURA, K. NISHIOKA
Journal: British Journal of Dermatology (1997)
The NAS Perchlorate Review: Ginsberg et al. Respond
Authors: Gary Ginsberg, Deborah Rice
Journal: Environmental Health Perspectives (2005)

Siemiatycki et al. (2004) published a list of occupational carcinogens based largely on the evaluations published by the International Agency for Research on Cancer (IARC), augmented with additional information on the extent of workplace exposure.They considered 28 agents as definite human occupational carcinogens (IARC group 1), 27 agents as probable occupational carcinogens (group 2A), and 113 agents as possible occupational carcinogens (group 2B).However, missing from their list of occupational carcinogens is magnetic fields (MFs) at extremely low frequencies (ELF; 3-3000-Hz), which were classified as group 2B by IARC ( 2002).IARC's final conclusion (IARC 2002) is as follows:Overall, extremely low frequency magnetic fields were evaluated as possibly carcinogenic to humans (IIB), based on the statistical association of higher level residential ELF magnetic fields and increased risk for childhood leukaemia.
Functional Somatic Syndromes
Authors: Arthur J. Barsky, Jonathan F. Borus
Journal: Annals of Internal Medicine (2000)

Letters15 February 2000Functional Somatic SyndromesArthur J. Barsky, MD and Jonathan F. Borus, MDArthur J. Barsky, MDBrigham and Women's Hospital; Boston, MA 02115 (Barsky)Brigham and Women's Hospital; Boston, MA 02115 (Borus)Search for more papers by this author and Jonathan F. Borus, MDBrigham and Women's Hospital; Boston, MA 02115 (Barsky)Brigham and Women's Hospital; Boston, MA 02115 (Borus)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-4-200002150-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:The correspondents make many different points, but several common themes emerge. The first is that our review failed to include evidence of demonstrable medical causes for some of the functional somatic syndromes. A review of such evidence was tangential to the main point of our report, which was that psychosocial factors and symptom amplifiers compound, perpetuate, and intensify symptoms that result from a variety of causes and that they make symptom relief more difficult to attain. We specifically did not assert that these psychosocial factors initiate the symptoms or are necessarily their primary cause. As we suggested in ... Author, Article, and Disclosure InformationAffiliations: Brigham and Women's Hospital; Boston, MA 02115 (Barsky)Brigham and Women's Hospital; Boston, MA 02115 (Borus) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFunctional Somatic Syndromes Arthur J. Barsky and Jonathan F. Borus Functional Somatic Syndromes Terry E. Hedrick Functional Somatic Syndromes James McSherry Functional Somatic Syndromes Kenneth Clemenger Functional Somatic Syndromes Allan Clemenger Functional Somatic Syndromes Ellen Goudsmit Functional Somatic Syndromes Melody Heard Functional Somatic Syndromes Frank Albrecht Functional Somatic Syndromes Thomas L. English Functional Somatic Syndromes Thomas L. Kurt Metrics Cited ByMedically unexplained physical symptoms in medical practice: a psychiatric perspective. 15 February 2000Volume 132, Issue 4Page: 329-330KeywordsBehaviorCardiovascular therapyDisabilitiesEmotionsMedical conditionsMotivationPsychologyPsychosocial stress Issue Published: 15 February 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Efforts aim at being more in touch with professions, public
Authors: C. Marwick
Journal: JAMA (1985)

For many years, the FDA seemed to fit the Churchillian description of Russia: "a riddle wrapped in a mystery inside an enigma." Today, the agency has shed a great deal of this image. "Within the past two or three years," says Stuart L. Nightingale, MD, associate commissioner for health affairs, "we have taken an active interest in the public proceedings of professional medical organizations. We try to clarify possible misconceptions about the FDA's position on an issue and correct mistakes when they arise." Last summer, Nightingale was at the American Medical Association's annual meeting in Chicago, for instance. He provided comments on resolutions and reports that were being considered by the AMA House of Delegates. Besides the AMA meetings and frequent "From the FDA" reports in The Journal, either Nightingale or a member of his staff attends meetings of other national medical groups such as the National Medical Association, and
Customary Fee
Authors: B. J. Bouche
Journal: BMJ (1959)

In February, 1959, at the age of 92, after a total of over 70,000 gr.(10+ lb.-4.7 kg.) of thyroid extract, she was symptom-free, active, and clinically euthyroid when she attended hospital for the 372nd time.Her old notes were studied, and it was considered that in 1895 she must have "had lymphadenoid goitre (described by Hashimoto in 1912 as struma lymphomatosa), which disease and its associated -myxoedema had been controlled ever since by thyroid therapy.It was fascinating to discover, even after 63 years, a trace (1/5) of thyroid auto-antibody with the tanned red- cell agglutination test.
Pregnancy May Veil Urinary Calculi
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM LONDON.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fundamentals of Chemistry. A Text-Book for Nurses and Other Students of Applied Chemistry.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Oncology (2018)

A targeted docetaxel nanoparticle will preferentially deliver drug to the tumor.Autio et al conducted a single-arm phase 2 trial of 42 chemotherapy-naive patients with progressing metastatic castration-resistant prostate cancer (mCRPC) after treatment with abiraterone acetate and/or enzalutamide by administering BIND-014, a docetaxel-containing nanoparticle targeting prostate-specific membrane antigen.A dosage of 60 mg/m 2 was given intravenously on day 1 of 21-day cycles in combination with prednisone until disease progression or unacceptable toxic effects occurred.A prostate-specific antigen response was observed in 12 of 40 patients (30%), measurable disease response in 6 of 19 (32%), and reductions in circulating tumor cells in 13 of 26 (50%).BIND-014 is active and well tolerated in patients with chemotherapy-naive mCRPC. Exercise and Mortality in Survivors of Childhood Cancer1352
Polymorphism of Human Acetyltransferases
Authors: Urs A. Meyer
Journal: Environmental Health Perspectives (1994)

Acetylation by arylamine N-acetyltransferases (NATs) is a major route in the metabolism of numerous drugs and carcinogens.Recent studies suggest that the same enzymes also catalyze N,O-transacetylation and O-acetylation.A genetic polymorphism of clinical relevance divides the human popu- lation into slow and rapid acetylators of arylamines.Two human NATs, NATl and NAT2, have recently been characterized by protein purification, cloning, and functional expression of the respective genes; both were localized to chromosome 8.NAT1 codes for a protein with ubiquitous tissue distribution and a high affinity for p-aminobenzoic acid and p-aminosalicylic acid, so-called monomorphic substrates.NAT2 codes for a protein pre- dominantly expressed in liver with a high affinity for sulfamethazine and other polymorphically metabolized drugs.NAT2 was analyzed at the level of protein, RNA and DNA derived from phenotyped slow and rapid acetylators.Two common (Ml, M2) and one rare (M3) mutant allele were identified and their mutations characterized.A simple polymerase chain reaction-based DNA test can identify >95% of mutant alleles and predict the pheno- type.-
Coronary artery calcium in older adults aged 67-99
Authors: Anne B Newman, Barbara L Naydeck, Kim Sutton-Tyrrell, Daniel Edmondowicz, Lewis H Kuller
Journal: Circulation (2001)

0001 Coronary artery calcification (CAC) appears to increase with age to at least age 75, but has not been studied in adults well beyond this age. Between 1998-2000, 614 of 767 participants from the Pittsburgh cohort of the Cardiovascular Health Study, mean age 80 years (range 67-99), had CAC measured by electron beam tomography (total Agatson score). All had prior clinical exams, non-invasive exams of carotid wall thickness, ankle-arm index, and ECG to detect subclinical CVD (’94- 95), and baseline risk factor assessment (’89- 90). Of the 614, 367 (60%) were women and 247(40%) were men; 23% were African American. The prevalence of clinical CVD at scan was 33%, and another 33% had at least one marker of subclinical CVD. CAC scores were skewed towards low scores, with a median of 625 for men and 202 for women. Median CAC score increased with age, were usually higher in men than women regardless of the presence or absence of clinical or subclinical CVD ( Table). No detectable CAC was found in 6% of men and 11% of women but the proportion with a zero score decreased with age (from 15% under age 80 to 5% of those 80+). Those with higher scores were also more likely to be Caucasian, but did not differ in prevalence of baseline hypertension, diabetes, or lipid levels. Smoking history was of borderline significance. These data suggest that CAC continues to increase in these survivors into advanced old age and is more strongly related to age than to baseline risk factors. Also of note, a small proportion remained free of detectable CAC past age 80. Table 1.
A pilot/phase II study of gemcitabine (G) and split dose cisplatin (C) in advanced or metastatic non-small cell lung cancer (NSCLC) in an outpatient setting
Authors: S. A. Hussain, D. H. Palmer, D. E. Swinson, C. Bailey, L. Billingham, P. Riley, A. El-Modir, D. W. Rea, A. D. Chetiyawardana, M. H. Cullen
Journal: Journal of Clinical Oncology (2005)

7272 Introduction: This is a pilot/phase II trial with GC on a 21-day cycle, with G and C split between d1, 8. Split dose C allowed administration in an outpatient setting. Objectives: To document the toxicity and define the objective response rate; and determine progression-free and overall survival. Methods: Pts with stage III/IV NSCLC received: G/C 1250/40mg/m2 (G and C given on d1, 8 every 3 wks). Eligibility: ECOG PS 0–2, adequate bone marrow/liver function, calculated GFR > 50 ml/min. Results: 37 pts enrolled, all evaluable for toxicity; 30 evaluable for response; 4 patients too early for response assessment and 3 patients did not complete 1 cycle of chemotherapy. Characteristics: 70% male, median age 66 yrs (range 41–77), 24% GFR 50- 60 ml/min, 62% Stage IV. Radiotherapy was allowed after completing chemotherapy. 103 cycles have been delivered. Number of cycles with hematological toxicity as follows: Grade 3: 4 anaemia, 11 neutropenia, 4 thrombocytopenia; Grade 4: 4 neutropenia, 2 thrombocytopenia. There was 1 episode of febrile neutropenia. Number of cycles with non-hematological toxicity as follows: Grade 4: 1 myocardial infarction (MI), 1 gastrointestinal (GI) bleed, 1 pulmonary embolism, 1 stroke; Grade 3: 2 nausea, 1 deep vein thrombosis, 3 chest infection; Grade 2: 2 renal toxicity, 1 seizure, 1 hypomagnesemia. Only 3 cycles deferred due to grade 4 neutropenia; 2 for renal toxicity (in one patient with diabetes and hypertension renal function declined after 1 cycle necessitating discontinuation of chemotherapy). 2 deaths occurred on treatment: 1 MI (patient with a previous history of MI); 1 GI bleed (on Aspirin). Overall ITT response rate was 30% (10/33: 1 CR+ 9 PR) (34% \(\frac{10}{30}\) for assessable pts). 25 patients are alive and median follow-up of all patients is 6 months (range 1–15). The one-year survival rate is 55%. This study continues recruitment. Conclusion: G plus C in a 21-day schedule is active and well tolerated in an outpatient setting. This modified regimen with cisplatin split between d1 and d8 and with inclusion criteria of GFR as low as 50mls/min widens the spectrum of patients receiving cisplatin-based chemotherapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly
Sodium bicarbonate administration during cardiac arrest. Effect on arterial pH PCO2, and osmolality
Authors: R. L. Bishop
Journal: JAMA (1976)

Arterial pH, Pco<sub>2</sub>, and osmolality were determined serially during cardiac resuscitation in patients and in dogs, with and without administration of sodium bicarbonate. These studies demonstrate that (1) in the absence of preexisting acidosis, severe acidosis can be prevented by adequate ventilation alone; (2) sodium bicarbonate administration results in a significant rise in arterial Pco<sub>2</sub>, which parallels the rise in pH despite adequate ventilation; (3) during prolonged cardiac arrest and resuscitation, there is a rise in arterial osmolality that is accentuated by sodium bicarbonate. These studies suggest that sodium bicarbonate should not be used during resuscitation (1) in the absence of effective hyperventilation or where carbon dioxide removal is inadequate despite adequate ventilation, (2) in repeated doses, without confirmation of substantial acidosis, or (3) when cardiac arrest has been of brief duration and preexisting acidosis is unlikely. These studies also point to the need for a reappraisal of other buffers that do not elevate the arterial Pco<sub>2</sub>. (<i>JAMA</i>235:506-509, 1976)
From the gene to behavior
Authors: S. Benzer
Journal: JAMA (1971)

The problem of gene structure and coding was exciting while it lasted. The story of the past two eventful decades, including my own contributions, has been well told,<sup>1-3</sup>and need not be repeated here. But molecular genetics, pursued to ever lower levels of organization, inevitably does away with itself: the gap between genetics and biochemistry disappears. More recently, a number of molecular biologists have turned their sights in the opposite direction, ie, up to higher integrative levels, to explore the relatively distant horizons of development, the nervous system, and behavior. When the individual develops from an egg, the one-dimensional information contained in the linear sequence of genes on the chromosomes is somehow translated into a two-dimensional blastula, which later folds to produce a precise three-dimensional array of sense organs, central nervous system, and muscles. Finally, the ensemble interacts to produce behavior, a phenomenon which requires four dimensions, at the